GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » 6-1 Month Momentum %

RNAZ (TransCode Therapeutics) 6-1 Month Momentum % : -69.13% (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is TransCode Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-12-15), TransCode Therapeutics's 6-1 Month Momentum % is -69.13%.

The industry rank for TransCode Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

RNAZ's 6-1 Month Momentum % is ranked worse than
93.75% of 1473 companies
in the Biotechnology industry
Industry Median: -9.53 vs RNAZ: -69.13

Competitive Comparison of TransCode Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, TransCode Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransCode Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's 6-1 Month Momentum % falls into.



TransCode Therapeutics  (NAS:RNAZ) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TransCode Therapeutics  (NAS:RNAZ) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


TransCode Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of TransCode Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


TransCode Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6 Liberty Square, Suite 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Executives
Robert Michael Dudley director, 10 percent owner, officer: Chief Executive Officer C/O TRANSCODE THERAPEUTICS, 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Thomas A Fitzgerald director, officer: VP, Chief Financial Officer C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Anna Moore 10 percent owner C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Zdravka Medarova 10 percent owner C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Erik Manting director C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109